Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

An expert discusses how recent trials address the unmet needs of UTI patients and highlights key areas where further research and collaboration are essential for improving patient outcomes.

and the first targeted therapy candidate to address the unmet clinical needs in DGC. The Phase I study, currently underway at Beijing Cancer Hospital in China, aims to evaluate the safety ...

Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally. ... Read ...

and the first targeted therapy candidate to address the unmet clinical needs in DGC. The phase I study, currently underway at Beijing Cancer Hospital in China, aims to evaluate the safety, ...

Investigational treatments—therapies not yet approved for market introduction—provide a beacon of hope for tackling complex diseases and unmet medical needs in healthcare.

The evolution of therapeutic strategies includes: Significant Opportunity in Asia-Pacific The Asia-Pacific region, with its genetic diversity and unmet clinical needs, remains a focal point for ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in its ...

US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy, troculeucel to treat moderate Alzheimer’s disease: Santa Ana, California Saturday, Februar ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) ...